Infectious Diseases And Therapy SCIE

国际简称：INFECT DIS THER 参考译名：传染病与治疗

主要研究方向：Medicine-Microbiology (medical) 非预警期刊审稿周期： 6 Weeks

《传染病与治疗》(Infectious Diseases And Therapy)是一本由Springer Healthcare出版的以Medicine-Microbiology (medical)为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q1 JCR分区
144 年发文量
4.7 IF影响因子
开放是否OA
2012 创刊年份
6 issues per year 出版周期
English 出版语言

Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.

[ 查看全部 ]

投稿咨询加急咨询

投稿热线：400-888-7501

Infectious Diseases And Therapy期刊信息

ISSN：2193-8229
出版语言：English
是否OA：开放
E-ISSN：2193-6382
出版地区：ENGLAND
是否预警：否
出版商：Springer Healthcare
出版周期：6 issues per year
创刊时间：2012
开源占比：0.9927
Gold OA文章占比：98.50%
OA被引用占比：1
出版国人文章占比：0.04
出版撤稿占比：0
研究类文章占比：77.78%

Infectious Diseases And Therapy CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

8.6

1.351

1.311

学科类别	分区	排名	百分位
大类：Medicine 小类：Infectious Diseases	Q1	61 / 344	82%
大类：Medicine 小类：Microbiology (medical)	Q1	31 / 140	78%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Infectious Diseases And Therapy中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	INFECTIOUS DISEASES 传染病学	3区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	INFECTIOUS DISEASES 传染病学	3区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	INFECTIOUS DISEASES 传染病学	4区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	2区	INFECTIOUS DISEASES 传染病学	2区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	INFECTIOUS DISEASES 传染病学	4区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	INFECTIOUS DISEASES 传染病学	3区

Infectious Diseases And Therapy JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：INFECTIOUS DISEASES	SCIE	Q1	20 / 132	85.2%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：INFECTIOUS DISEASES	SCIE	Q1	32 / 132	76.14%

Infectious Diseases And Therapy历年数据统计

影响因子

中科院分区

Infectious Diseases And Therapy中国学者发文选摘

1、Non-invasive Assessment of Liver Fibrosis Regression in Patients with Chronic Hepatitis B: A Retrospective Cohort Study
Author: Xu, Wei; Hu, Qiankun; Chen, Chong; Li, Weixia; Li, Qiang; Chen, Liang

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 487-498. DOI: 10.1007/s40121-022-00738-1
2、Retrospective Analysis of Epidemiology, Risk Factors, and Outcomes of Health Care-Acquired Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in a Chinese Tertiary Hospital, 2010-2019
Author: Li, Meng; Yang, Shanshan; Yao, Hongwu; Liu, Yunxi; Du, Mingmei

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 473-485. DOI: 10.1007/s40121-022-00732-7
3、Association Between Lactate and 28-Day Mortality in Elderly Patients with Sepsis: Results from MIMIC-IV Database
Author: He, Liudang; Yang, Donghua; Ding, Qiong; Su, Yingjie; Ding, Ning

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 459-472. DOI: 10.1007/s40121-022-00736-3
4、Comparison of the Distribution and Changes in the Antibiotic Resistance of Clinical Bacterial Isolates from the Lower Respiratory Tract of Children in Shenzhen Before the Epidemic, During the Epidemic, and During the Period of Normalized Prevention and Control of COVID-19
Author: Meng, Qing; Li, Wujiao; Jiang, Hanfang; Yan, Huimin; Wang, Heping; Ye, Binjun; Zhou, Lintao; Chen, Yunsheng

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 563-575. DOI: 10.1007/s40121-022-00751-4
5、The Association Between Alveolar-Arterial Oxygen Tension Difference and the Severity of COVID-19 in Patients
Author: Xie, Canbin; Deng, Jiayi; Li, Fanglin; Wu, Chenfang; Xu, Min; Yu, Bo; Wu, Guobao; Zhong, Yanjun; Tang, Da; Li, Jinxiu

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 577-587. DOI: 10.1007/s40121-022-00752-3
6、Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients
Author: Weng, Chengzhao; Xie, Rongcheng; Han, Guanjie; Yuan, Ya; Li, Shiqin; Wang, Chao; Wang, Xiaofeng; Jiang, Wei; Jiang, Libo

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 649-662. DOI: 10.1007/s40121-023-00760-x
7、Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults
Author: Chen, Guiling; Li, Nan; Dai, Xiahong; Tu, Shiyan; Shen, Zhenwei; Wu, Kaiqi; Jin, Tinghan; Wu, Jiajun; Peng, Conggao; Sheng, Guoping; Zhu, Mengfei; Tang, Lingling; Li, Lanjuan

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 663-675. DOI: 10.1007/s40121-023-00759-4
8、Effect of Anti-HBs on Mortality Among Resolved HBV Infection: a Population-Based Prospective Cohort Study
Author: Huang, Shuai-Wen; Li, Xi-Tang; Chen, Chen; Ning, Qin; Huang, Jia-Quan

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 3, pp. 871-890. DOI: 10.1007/s40121-023-00766-5